1. Pink Sheet
  2. >>Vaccines

Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide

 
• By Andrew McConaghie and Vibha Ravi

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.

INDIA’S COVID OUTBREAK IS BEGINNING TO PLAY AN OUTSIZED ROLE IN THE SHAPE OF THE PANDEMIC.

International biopharma industry leaders have called on the US government to ease its current controls on supplies of raw materials for COVID-19 vaccines in order to help India combat its explosive outbreak.

However, the White House has responded to criticism of the Defense Production Act (DPA) by denying that it is restricting exports, and the tussle between industry and the Biden administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Darzalex Faspro Gains US FDA AdComm Support For Smoldering Myeloma Claim

 
• By Bridget Silverman

The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.

STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By Sue Sutter

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.